FNCH Stock Overview
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Finch Therapeutics Group, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.52 |
| 52 Week High | US$16.74 |
| 52 Week Low | US$1.86 |
| Beta | 0.46 |
| 1 Month Change | -7.35% |
| 3 Month Change | -16.17% |
| 1 Year Change | -78.13% |
| 3 Year Change | -99.40% |
| 5 Year Change | n/a |
| Change since IPO | -99.61% |
Recent News & Updates
Recent updates
Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration
Sep 01Finch to get back rights to IBD product candidates after Takeda ends collaboration
Aug 25Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M
Aug 11Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Mar 15
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Dec 15We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully
Aug 28Finch Therapeutics: Gut Instinct Says Buy
Jun 14Shareholder Returns
| FNCH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 2.9% | -4.2% | -3.7% |
| 1Y | -78.1% | -2.0% | 20.5% |
Return vs Industry: FNCH underperformed the US Biotechs industry which returned -1.7% over the past year.
Return vs Market: FNCH underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| FNCH volatility | |
|---|---|
| FNCH Average Weekly Movement | 19.7% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.4% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: FNCH's share price has been volatile over the past 3 months.
Volatility Over Time: FNCH's weekly volatility (20%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2014 | 1 | Matt Blischak | www.finchtherapeutics.com |
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States. The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524, FIN-525, and other microbiome product candidates for inflammatory bowel disease. The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; Skysong Innovations LLC; and University of Minnesota.
Finch Therapeutics Group, Inc. Fundamentals Summary
| FNCH fundamental statistics | |
|---|---|
| Market cap | US$4.98m |
| Earnings (TTM) | -US$74.75m |
| Revenue (TTM) | US$107.00k |
37.8x
P/S Ratio-0.1x
P/E RatioIs FNCH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FNCH income statement (TTM) | |
|---|---|
| Revenue | US$107.00k |
| Cost of Revenue | US$7.20m |
| Gross Profit | -US$7.09m |
| Other Expenses | US$67.66m |
| Earnings | -US$74.75m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -46.55 |
| Gross Margin | -6,628.04% |
| Net Profit Margin | -69,863.55% |
| Debt/Equity Ratio | 0% |
How did FNCH perform over the long term?
See historical performance and comparison